Samsung Asset Management (New York)’s Teva Pharmaceuticals TEVA Stock Holding History

Samsung Asset Management (New York)’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-18,840	Closed	-$1.01M	–	82
2014 Q3	$1.01M	Sell	18,840 -210	-1%	-$11.1K	0.32%	69
2014 Q2	$999K	Sell	19,050 -17,890	-48%	-$914K	0.31%	72
2014 Q1	$1.95M	Sell	36,940 -34,320	-48%	-$1.59M	0.69%	53
2013 Q4	$2.86M	Buy	+71,260	New	+$2.81M	0.95%	49

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Samsung Asset Management (New York)'s TEVA Position: Q4 2014 in Review

Samsung Asset Management (New York) sold out of Teva Pharmaceuticals (TEVA) in Q4 2014, closing a stake of 18,840 shares — an estimated $1.01M sold.

Samsung Asset Management (New York) first reported a position in TEVA in Q4 2013 and held it in 4 quarters. The position peaked at $2.86M in Q4 2013. 822 funds tracked by Wall St. Rank hold TEVA as of Q4 2014.

Samsung Asset Management (New York) reported no remaining Teva Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Samsung Asset Management (New York) sold 18,840 Teva Pharmaceuticals shares in Q4 2014, an estimated $1.01M.
Samsung Asset Management (New York) first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 4 quarters.
Samsung Asset Management (New York)'s Teva Pharmaceuticals position peaked at $2.86M in Q4 2013.
822 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2014.

Based on Samsung Asset Management (New York)'s 13F filing for Q4 2014, filed 11 Feb 2015.